Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Haass, Nikolas K ^a,b,c   Nassif, Najah ^d   McGowan, Eileen M ^d,e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b CENTENARY INSTITUTE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 2 [2 [4 (3 BENZYLOXYPHENYLTHIO) 2 CHLOROPHENYL]ETHYL] 1,3 PROPANEDIOL; 4 (2,6 DICHLORO 4 PYRIDINYL) 1 (1,3 DIMETHYL 4 ISOPROPYL 1H PYRAZOLO[3,4 B]PYRIDIN 6 YL)SEMICARBAZIDE; AGENTS AFFECTING PROTEIN METABOLISM; ANTINEOPLASTIC AGENT; CERAMIDE; CS 0777; FINGOLIMOD; GSK 2018682; METFORMIN; PONESIMOD; RPC 0163; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE INHIBITOR; SPHINGOSINE KINASE; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG; SPHINGOLIPID;

COMORBIDITY; DIABETES MELLITUS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; DIABETES MELLITUS, TYPE 2; METABOLISM; NEOPLASMS;

COMORBIDITY; DIABETES MELLITUS, TYPE 2; HUMANS; NEOPLASMS; SPHINGOLIPIDS;

EID: 84926442224     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/165105     Document Type: Review

References (109)

1. G. Danaei, M. M. Finucane, Y. Lu et al., "National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants," The Lancet, vol. 378, no. 9785, pp. 31-40, 2011.
2. WHO, Global Status Report on Noncommunicable Diseases 2010, WHO, Geneva, Switzerland, 2011.
3. J. Ferlay, I. Soerjomataram, M. Ervik et al., GLOBOCAN 2012 v1.0, IARC Cancer Base No. 11, Cancer Incidence and Mortality Worldwide, 2012.
4. F. Bray, J.-S. Ren, E. Masuyer, and J. Ferlay, "Global estimates of cancer prevalence for 27 sites in the adult population in 2008," International Journal of Cancer, vol. 132, no. 5, pp. 1133-1145, 2013.
5. S. Sen, Y. He, D. Koya, and K. Kanasaki, "Cancer biology in diabetes," Journal of Diabetes Investigation, vol. 5, no. 3, pp. 251-264, 2014.
6. S. K. Garg, H. Maurer, K. Reed, and R. Selagamsetty, "Diabetes and cancer: two diseases with obesity as a common risk factor," Diabetes, Obesity and Metabolism, vol. 16, no. 2, pp. 97-110, 2014.
7. M. J. Khandekar, P. Cohen, and B. M. Spiegelman, "Molecular mechanisms of cancer development in obesity," Nature Reviews Cancer, vol. 11, no. 12, pp. 886-895, 2011.
8. E. Giovannucci, D. M. Harlan, M. C. Archer et al., "Diabetes and cancer: a consensus report," Diabetes Care, vol. 33, no. 7, pp. 1674-1685, 2010.
9. B. B. Barone, H.-C. Yeh, C. F. Snyder et al., "Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis," The Journal of the American Medical Association, vol. 300, no. 23, pp. 2754-2764, 2008.
10. H. Noto, A. Goto, T. Tsujimoto, K. Osame, and M. Noda, "Latest insights into the risk of cancer in diabetes," Journal of Diabetes Investigation, vol. 4, no. 3, pp. 225-232, 2013.
11. M. Jalving, J. A. Gietema, J. D. Lefrandt et al., "Metformin: taking away the candy for cancer?" European Journal of Cancer, vol. 46, no. 13, pp. 2369-2380, 2010.
12. M. Maceyka, K. B. Harikumar, S. Milstien, and S. Spiegel, "Sphingosine-1-phosphate signaling and its role in disease," Trends in Cell Biology, vol. 22, no. 1, pp. 50-60, 2012.
13. J.-P. Truman, M. García-Barros, L. M. Obeid, and Y. A. Hannun, "Evolving concepts in cancer therapy through targeting sphin-golipid metabolism," Biochimica et Biophysica Acta, vol. 1841, no. 8, pp. 1174-1188, 2014.
14. L. A. Heffernan-Stroud and L. M. Obeid, "Sphingosine kinase 1 in cancer," Advances in Cancer Research, vol. 117, pp. 201-235, 2013.
15. D. Plano, S. Amin, and A. K. Sharma, "Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors," Journal of Medicinal Chemistry, vol. 7, no. 13, pp. 5509-5524, 2014.
16. C. R. Bruce, S. Risis, J. R. Babb et al., "Overexpression of sphingosine kinase 1 prevents ceramide accumulation and ameliorates muscle insulin resistance in high-fat diet-fed mice," Diabetes, vol. 61, no. 12, pp. 3148-3155, 2012.
17. M. M. Ma, J. L. Chen, G. G. Wang et al., "Sphingosine kinase 1 participates in insulin signalling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice," Diabetologia, vol. 50, no. 4, pp. 891-900, 2007.
18. Y. A. Hannun and L. M. Obeid, "Principles of bioactive lipid signalling: lessons from sphingolipids," Nature Reviews Molecular Cell Biology, vol. 9, no. 2, pp. 139-150, 2008.
19. A. Olivera and S. Spiegel, "Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens," Nature, vol. 365, no. 6446, pp. 557-560, 1993.
20. i-coupled receptor Edg-1 and intracellular to regulate proliferation and survival," The Journal of Cell Biology, vol. 142, no. 1, pp. 229-240, 1998.
21. "Report of the expert committee on the diagnosis and classification of diabetes mellitus," Diabetes Care, vol. 26, supplement 1, pp. S5-S20, 2003.
22. M. Cnop, N. Welsh, J.-C. Jonas, A. Jörns, S. Lenzen, and D. L. Eizirik, "Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes: many differences, few similarities," Diabetes, vol. 54, no. 2, pp. S97-S107, 2005.
23. S. Shao, Y. Yang, G. Yuan, M. Zhang, and X. Yu, "Signaling molecules involved in lipid-induced pancreatic beta-cell dysfunction," DNA and Cell Biology, vol. 32, no. 2, pp. 41-49, 2013.
24. P. Newsholme, D. Keane, H. J. Welters, and N. G. Morgan, "Life and death decisions of the pancreatic β-cell: the role of fatty acids," Clinical Science, vol. 112, no. 1-2, pp. 27-42, 2007.
25. E. Phielix and M. Mensink, "Type 2 diabetes mellitus and skeletal muscle metabolic function," Physiology and Behavior, vol. 94, no. 2, pp. 252-258, 2008.
26. J. A. Johnson and M. Pollak, "Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes," Diabetologia, vol. 53, no. 10, pp. 2086-2088, 2010.
27. C. Li and D. Kong, "Cancer risks from diabetes therapies: evaluating the evidence," Pharmacology & Therapeutics, vol. 144, no. 1, pp. 71-81, 2014.
28. L. Braccini, E. Ciraolo, M. Martini et al., "PI3K keeps the balance between metabolism and cancer," Advances in Biological Regulation, vol. 52, no. 3, pp. 389-405, 2012.
29. R. Zoncu, A. Efeyan, and D. M. Sabatini, "mTOR: From growth signal integration to cancer, diabetes and ageing," Nature Reviews Molecular Cell Biology, vol. 12, no. 1, pp. 21-35, 2011.
30. K. A. Orr Gandy and L. M. Obeid, "Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors," Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1831, no. 1, pp. 157-166, 2013.
31. N. J. Pyne and S. Pyne, "Sphingosine 1-phosphate and cancer," Nature Reviews Cancer, vol. 10, no. 7, pp. 489-503, 2010.
32. N. J. Pyne, F. Tonelli, K. G. Lim et al., "Targeting sphingosine kinase 1 in cancer," Biochemical Society Transactions, vol. 40, no. 1, pp. 94-100, 2012.
33. Y. A. Hannun, C. R. Loomis, A. H. Merrill Jr., and R. M. Bell, "Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets," The Journal of Biological Chemistry, vol. 261, no. 27, pp. 12604-12609, 1986.
34. S. Milstien and S. Spiegel, "Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics," Cancer Cell, vol. 9, no. 3, pp. 148-150, 2006.
35. R. Alemany, C. J. van Koppen, K. Danneberg, M. Ter Braak, and D. M. Zu Heringdorf, "Regulation and functional roles of sphingosine kinases," Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 374, no. 5-6, pp. 413-428, 2007.
36. H. J. Abuhusain, A. Matin, Q. Qiao et al., "A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis," The Journal of Biological Chemistry, vol. 288, no. 52, pp. 37355-37364, 2013.
37. N. C. Hait, C. A. Oskeritzian, S. W. Paugh, S. Milstien, and S. Spiegel, "Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases," Biochimica et Biophysica Acta, vol. 1758, no. 12, pp. 2016-2026, 2006.
38. K. Mendelson, T. Evans, and T. Hla, "Sphingosine 1-phosphate signalling," Development, vol. 141, no. 1, pp. 5-9, 2014.
39. E. Rapizzi, M. L. Taddei, T. Fiaschi, C. Donati, P. Bruni, and P. Chiarugi, "Sphingosine 1-phosphate increases glucose uptake through trans-activation of insulin receptor," Cellular and Molecular Life Sciences, vol. 66, no. 19, pp. 3207-3218, 2009.
40. M. Schüppel, U. Kürschner, U. Kleuser, M. Schäfer-Korting, and B. Kleuser, "Sphingosine 1-phosphate restrains insulinmediated keratinocyte proliferation via inhibition of Akt through the S1P2 receptor subtype," The Journal of Investigative Dermatology, vol. 128, no. 7, pp. 1747-1756, 2008.
41. D. Yagoub, M. R. Wilkins, A. J. Lay et al., "Sphingosine kinase 1 isoform-specific interactions in breast cancer," Molecular Endocrinology, vol. 28, no. 11, pp. 1899-1915, 2014.
42. K. G. Lim, F. Tonelli, E. Berdyshev et al., "Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: functional differences between sphingosine kinase 1a and 1b," The International Journal of Biochemistry & Cell Biology, vol. 44, no. 9, pp. 1457-1464, 2012.
43. Y. Qi, J. Chen, A. Lay, A. Don, M. Vadas, and P. Xia, "Loss of sphingosine kinase 1 predisposes to the onset of diabetes via promoting pancreatic β-cell death in diet-induced obese mice," FASEB Jour nal, vol. 27, no. 10, pp. 4294-4304, 2013.
44. W. L. Holland, J. T. Brozinick, L.-P. Wang et al., "Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance," Cell Metabolism, vol. 5, no. 3, pp. 167-179, 2007.
45. C. F. Jessup, C. S. Bonder, S. M. Pitson, and P. T. H. Coates, "The sphingolipid rheostat: a potential target for improving pancreatic islet survival and function," Endocrine, Metabolic and Immune Disorders: Drug Targets, vol. 11, no. 4, pp. 262-272, 2011.
46. N. M. Hasan, M. J. Longacre, S. W. Stoker et al., "Sphingosine kinase 1 knockdown reduces insulin synthesis and secretion in a rat insulinoma cell line," Archives of Biochemistry and Biophysics, vol. 518, no. 1, pp. 23-30, 2012.
47. W. L. Holland, R. A. Miller, Z. V. Wang et al., "Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin," Nature Medicine, vol. 17, no. 1, pp. 55-63, 2011.
48. C. Tao, A. Sifuentes, and W. L. Holland, "Regulation of glucose and lipid homeostasis by adiponectin: effects on hepatocytes, pancreatic β cells and adipocytes," Best Practice & Research: Clinical Endocrinology and Metabolism, vol. 28, no. 1, pp. 43-58, 2014.
49. H. Iwatsuka, A. Shino, and Z. Suzuoki, "General survey of diabetic features of yellow KK mice," Endocrinologia Japonica, vol. 17, no. 1, pp. 23-35, 1970.
50. O. Schnell, F. Cappuccio, S. Genovese, E. Standl, P. Valensi, and A. Ceriello, "Type 1 diabetes and cardiovascular disease," Cardiovascular Diabetology, vol. 12, no. 1, article 156, 2013.
51. F. Paneni, J. A. Beckman, M. A. Creager, and F. Cosentino, "Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I," European Heart Journal, vol. 34, no. 31, pp. 2436-2443, 2013.
52. S. M. Grundy, I. J. Benjamin, G. L. Burke et al., "Diabetes and cardiovascular disease: a statement for healthcare professionals from the american heart association," Circulation, vol. 100, no. 10, pp. 1134-1146, 1999.
53. P. Fioretto, P. M. Dodson, D. Ziegler, and R. S. Rosenson, "Residual microvascular risk in diabetes: unmet needs and future directions," Nature Reviews Endocrinology, vol. 6, no. 1, pp. 19-25, 2010.
54. F. Paneni, S. Costantino, and F. Cosentino, "Insulin resistance, diabetes, and cardiovascular risk," Current Atherosclerosis Reports, vol. 16, no. 7, article 419, 2014.
55. H. Li, S. Horke, and U. Forstermann, "Vascular oxidative stress, nitric oxide and atherosclerosis," Atherosclerosis, vol. 237, pp. 208-219, 2014.
56. P. Keul, K. Sattler, and B. Levkau, "HDL and its sphingosine-1-phosphate content in cardioprotection," Heart Failure Reviews, vol. 12, no. 3-4, pp. 301-306, 2007.
57. J. S. Karliner, "Sphingosine kinase regulation and cardioprotection," Cardiovascular Research, vol. 82, no. 2, pp. 184-192, 2009.
58. J. S. Karliner, "Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress," Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1831, no. 1, pp. 203-212, 2013.
59. S. Penpargkul, T. Schaible, T. Yipintsoi, and J. Scheuer, "The effect of diabetes on performance and metabolism of rat hearts," Circulation Research, vol. 47, no. 6, pp. 911-921, 1980.
60. K. Dahl-Jørgensen, J. R. Larsen, and K. F. Hanssen, "Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment?" Diabetologia, vol. 48, no. 8, pp. 1445-1453, 2005.
61. M. Fisher, "Diabetes and atherogenesis," Heart, vol. 90, no. 3, pp. 336-340, 2004.
62. R. Donnelly and K. R. Davis, "Type 2 diabetes and atherosclerosis," Diabetes, Obesity and Metabolism, vol. 2, no. 1, pp. S21-S30, 2000.
63. J. Mestas and K. Ley, "Monocyte-endothelial cell interactions in the development of atherosclerosis," Trends in Cardiovascular Medicine, vol. 18, no. 6, pp. 228-232, 2008.
64. A. M. Whetzel, D. T. Bolick, and C. C. Hedrick, "Sphingosine-1-phosphate inhibits high glucose-mediated ERK1/2 action in endothelium through induction of MAP kinase phosphatase-3," American Journal of Physiology: Cell Physiology, vol. 296, no. 2, pp. C339-C345, 2009.
65. A. M. Whetzel, D. T. Bolick, S. Srinivasan et al., "Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor," Circulation Research, vol. 99, no. 7, pp. 731-739, 2006.
66. H. A. Khafaji and J. M. Suwaidi, "A typical presentation of acute and chronic coronary artery disease in diabetics," World Journal of Cardiology, vol. 6, no. 8, pp. 802-813, 2014.
67. Z.-Q. Jin, J. S. Karliner, and D. A. Vessey, "Ischaemic postconditioning protects isolated mouse hearts against ischaemia/reperfusion injury via sphingosine kinase isoform-1 activation," Cardiovascular Research, vol. 79, no. 1, pp. 134-140, 2008.
68. D. A. Vessey, M. Kelley, L. Li, and Y. Huang, "Sphingosine protects aging hearts from ischemia/reperfusion injury: superiority to sphingosine 1-phosphate and ischemic pre- and post-conditioning," Oxidative Medicine and Cellular Longevity, vol. 2, no. 3, pp. 146-151, 2009.
69. D. A. Vessey, M. Kelley, L. Li et al., "Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury," Medical Science Monitor, vol. 12, no. 10, pp. BR318-BR324, 2006.
70. C. S. Bonder, W. Y. Sun, T. Matthews et al., "Sphingosine kinase regulates the rate of endothelial progenitor cell differentiation," Blood, vol. 113, no. 9, pp. 2108-2117, 2009.
71. H. Yu, L. Yuan, M. Xu, Z. Zhang, and H. Duan, "Sphingosine kinase 1 improves cutaneous wound healing in diabetic rats," Injury, vol. 45, no. 7, pp. 1054-1058, 2014.
72. Y. Osawa, H. Uchinami, J. Bielawski, R. F. Schwabe, Y. A. Hannun, and D. A. Brenner, "Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-α," The Journal of Biological Chemistry, vol. 280, no. 30, pp. 27879-27887, 2005.
73. G. M. Kowalski, A. L. Carey, A. Selathurai, B. A. Kingwell, and C. R. Bruce, "Plasma sphingosine-1-phosphate is elevated in obesity," PLoS ONE, vol. 8, no. 9, Article ID e72449, 2013.
74. J. Wang, L. Badeanlou, J. Bielawski, T. P. Ciaraldi, and F. Samad, "Sphingosine kinase 1 regulates adipose proinflammatory responses and insulin resistance," American Journal of Physiology: Endocrinology and Metabolism, vol. 306, no. 7, pp. E756-E768, 2014.
75. M. Tous, R. Ferrer-Lorente, and L. Badimon, "Selective inhibition of sphingosine kinase-1 protects adipose tissue against LPS-induced inflammatory response in Zucker diabetic fatty rats," The American Journal of Physiology, Endocrinology and Metabolism, vol. 307, no. 5, pp. E437-E446, 2014.
76. H. Furuya, M. Wada, Y. Shimizu et al., "Effect of sphingosine kinase 1 inhibition on blood pressure," The FASEB Journal, vol. 27, no. 2, pp. 656-664, 2013.
77. Z. Yin, L. Fan, L. Wei et al., "FTY720 protects cardiac microvessels of diabetes: a critical role of S1P1/3 in diabetic heart disease," PLoS ONE, vol. 7, no. 8, Article ID e42900, 2012.
78. K. Janes, J. W. Little, C. Li et al., "The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1," The Journal of Biological Chemistry, vol. 289, no. 30, pp. 21082-21097, 2014.
79. H. Guan, L. Song, J. Cai et al., "Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells," PLoS ONE, vol. 6, no. 5, Article ID e19946, 2011.
80. B. Xie, J. Shen, A. Dong, A. Rashid, G. Stoller, and P. A. Campochiaro, "Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization," Journal of Cellular Physiology, vol. 218, no. 1, pp. 192-198, 2009.
81. L. W. Maines, K. J. French, E. B. Wolpert, D. A. Antonetti, and C. D. Smith, "Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases," Investigative Ophthalmolog y and Visual Science, vol. 47, no. 11, pp. 5022-5031, 2006.
82. R. A. Sabbadini, "Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration," British Journal of Pharmacology, vol. 162, no. 6, pp. 1225-1238, 2011.
83. B. Visentin, J. A. Vekich, B. J. Sibbald et al., "Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages," Cancer Cell, vol. 9, no. 3, pp. 225-238, 2006.
84. K. Mizugishi, T. Yamashita, A. Olivera, G. F. Miller, S. Spiegel, and R. L. Proia, "Essential role for sphingosine kinases in neural and vascular development," Molecular and Cellular Biology, vol. 25, no. 24, pp. 11113-11121, 2005.
85. T. Lan, W. Liu, X. Xie et al., "Sphingosine kinase-1 pathway mediates high glucose-induced fibronectin expression in glomerular mesangial cells," Molecular Endocrinology, vol. 25, no. 12, pp. 2094-2105, 2011.
86. S. Fayyaz, J. Henkel, L. Japtok et al., "Involvement of sphingosine 1-phosphate in palmitate-induced insulin resistance of hepatocytes via the S1P2 receptor subtype," Diabetologia, vol. 57, no. 2, pp. 373-382, 2014.
87. S. Fayyaz, L. Japtok, and B. Kleuser, "Divergent role of sphingosine 1-phosphate on insulin resistance," Cellular Physiology and Biochemistry, vol. 34, pp. 134-147, 2014.
88. M. Bigaud, D. Guerini, A. Billich, F. Bassilana, and V. Brinkmann, "Second generation S1P pathway modulators: research strategies and clinical developments," Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1841, no. 5, pp. 745-758, 2014.
89. A. Huwiler and J. Pfeilschifter, "New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets," Biochemical Pharmacology, vol. 75, no. 10, pp. 1893-1900, 2008.
90. P. Bandhuvula, Y. Y. Tam, B. Oskouian, and J. D. Saba, "The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity," The Journal of Biological Chemistry, vol. 280, no. 40, pp. 33697-33700, 2005.
91. N. C. Kaneider, J. Lindner, C. Feistritzer et al., "The immune modulator FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid betaprotein and its precursor," The FASEB Journal, vol. 18, no. 11, pp. 1309-1311, 2004.
92. V. Brinkmann, M. D. Davis, C. E. Heise et al., "The immune modulator FTY720 targets sphingosine 1-phosphate receptors," Journal of Biological Chemistry, vol. 277, no. 24, pp. 21453-21457, 2002.
93. V. A. Blaho and T. Hla, "An update on the biology of sphingosine 1-phosphate receptors," The Journal of Lipid Research, vol. 55, no. 8, pp. 1596-1608, 2014.
94. I. Cristobal, R. Manso, and R. Rincon, "PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential," Molecular Cancer Therapeutics, vol. 13, no. 4, pp. 938-947, 2014.
95. P. Neviani, R. Santhanam, J. J. Oaks et al., "FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia," The Journal of Clinical Investigation, vol. 117, no. 9, pp. 2408-2421, 2007.
96. M. Nagahashi, N. C. Hait, M. Maceyka et al., "Sphingosine-1-phosphate in chronic intestinal inflammation and cancer," Advances in Biological Regulation, vol. 54, no. 1, pp. 112-120, 2014.
97. J. Liang, M. Nagahashi, E. Y. Kim et al., "Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer," Cancer Cell, vol. 23, no. 1, pp. 107-120, 2013.
98. Q. Liu, X. Zhao, F. Frissora et al., "FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma," Blood, vol. 111, no. 1, pp. 275-284, 2008.
99. R. Mani, Y. Mao, F. W. Frissora et al., "Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B cell cytotoxicity in chronic lymphocytic leukemia," Leukemia, 2014.
100. N. Zhang, Y. Qi, C. Wadham et al., "FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy," Autophagy, vol. 6, no. 8, pp. 1157-1167, 2010.
101. S. Baldacchino, C. Saliba, V. Petroni et al., "Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720," EPMA Journal, vol. 5, no. 1, article 3, 2014.
102. G. Marvaso, A. Barone, N. Amodio et al., "Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro," Cancer Biology & Therapy, vol. 15, no. 6, pp. 797-805, 2014.
103. S. Buddaseth, W. Göttmann, R. Blasczyk, and T. Huyton, "Overexpression of the pp32r1 (ANP32C) oncogene or its functional mutant pp32r1Y140H confers enhanced resistance to FTY720 (Finguimod)," Cancer Biology and Therapy, vol. 15, no. 3, pp. 289-296, 2014.
104. M. S. McDermott, B. C. Browne, N. T. Conlon et al., "PP2A inhibition overcomes acquired resistance to HER2 targeted therapy," Molecular Cancer, vol. 13, p. 157, 2014.
105. S.-Y. Park, M.-H. Moon, J.-K. Jeong et al., "Antiobesity activity of a sphingosine 1-phosphate analogue FTY720 observed in adipocytes and obese mouse model," Experimental and Molecular Medicine, vol. 44, no. 10, pp. 603-614, 2012.
106. C. R. Bruce, S. Risis, J. R. Babb et al., "The sphingosine-1-phosphate analog FTY720 reduces muscle ceramide content and improves glucose tolerance in high fat-fed male mice," Endocrinology, vol. 154, no. 1, pp. 65-76, 2013.
107. T. Maki, R. Gottschalk, N. Ogawa, and A. P. Monaco, "Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720," Transplantation, vol. 79, no. 9, pp. 1051-1055, 2005.
108. H. Moon, J. Chon, J. Joo et al., "FTY720 preserved islet β-cell mass by inhibiting apoptosis and increasing survival of β-cells in db/db mice," Diabetes/Metabolism Research and Reviews, vol. 29, no. 1, pp. 19-24, 2013.
109. T. Imasawa, K. Koike, I. Ishii, J. Chun, and Y. Yatomi, "Blockade of sphingosine 1-phosphate receptor 2 signaling attenuates streptozotocin-induced apoptosis of pancreatic β-cells," Biochemical and Biophysical Research Communications, vol. 392, no. 2, pp. 207-211, 2010.